Androgen Deprivation Therapy in Japanese Males with Osteoporosis: Efficacy and Challenges

Herues Inui^*
*Correspondence: Herues Inui, Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan, Email:

Keywords

Laminectomy • Human • Osteoarthritis

Introduction

Osteoporosis is a systemic skeletal disorder characterized by decreased bone density and increased fracture risk. While it is often considered a condition primarily affecting postmenopausal women, osteoporosis also significantly impacts men, particularly as they age. In Japan, a unique approach involves the use of androgen deprivation therapy in males with osteoporosis. This article explores the rationale, efficacy, and challenges of using ADT in the treatment of osteoporosis in Japanese males, providing a comprehensive review of current practices and future directions. ADT is associated with increased cardiovascular risks, including myocardial infarction and stroke. These risks necessitate careful cardiovascular monitoring and management in patients undergoing ADT for osteoporosis. ADT can lead to adverse metabolic changes, such as insulin resistance, increased body fat, and dyslipidemia. These changes can exacerbate the risk of metabolic syndrome and diabetes, requiring comprehensive metabolic monitoring and intervention. Given that testosterone generally promotes bone health, the use of ADT, which lowers testosterone, presents a paradox. Understanding the mechanisms by which ADT may stabilize or improve bone density in certain contexts is an area of ongoing research. Not all men with osteoporosis are suitable candidates for ADT. Patient selection should be based on a comprehensive assessment of bone health, fracture risk, and overall health status. Men with concurrent prostate cancer and osteoporosis may be more likely to receive ADT as part of their treatment plan. The decision to use ADT in osteoporosis must balance the potential benefits in bone health against the significant risks of adverse effects. A personalized approach, considering individual patient risk factors and preferences, is essential. Bisphosphonates, such as alendronate and zoledronic acid, are well-established treatments for osteoporosis. These agents inhibit bone resorption and have been shown to reduce fracture risk in men. Combining bisphosphonates with ADT may offer synergistic benefits, improving bone density while mitigating some of the adverse effects of ADT. Denosumab is a monoclonal antibody that inhibits the receptor activator of nuclear factor kappa-Β ligand, reducing bone resorption. Denosumab has been shown to increase BMD and reduce fracture risk in men with osteoporosis, including those receiving ADT for prostate cancer. It represents a promising adjunctive therapy in this population [1,2].

Literature Review

Osteoporosis in men is underrecognized and undertreated compared to women, despite its serious implications. In Japan, the aging population has led to an increase in the prevalence of osteoporosis among men. Fractures related to osteoporosis, such as hip and vertebral fractures, can result in significant morbidity, reduced quality of life, and increased mortality. The burden of osteoporosis-related fractures in men is substantial, necessitating effective treatment strategies. Bone remodeling is a dynamic process involving bone resorption by osteoclasts and bone formation by osteoblasts. In men, androgens, particularly testosterone, play a crucial role in maintaining bone density by promoting osteoblast activity and inhibiting osteoclast formation. Age-related decline in testosterone levels contributes to decreased bone density and increased fracture risk in men [3,4].

Discussion

Androgen deprivation therapy traditionally involves reducing androgen levels to treat conditions such as prostate cancer. ADT can be achieved through surgical castration or pharmacological agents, such as luteinizing hormone-releasing hormone agonists, LHRH antagonists, and anti-androgens. The primary goal of ADT is to lower testosterone levels, which is believed to reduce cancer cell growth and proliferation. The application of ADT in osteoporosis is unconventional, given that testosterone is typically protective against bone loss. However, in certain clinical scenarios, reducing androgen levels can influence bone remodeling processes. Understanding the rationale and implications of ADT in the context of osteoporosis requires a nuanced discussion. Limited studies have explored the direct impact of ADT on fracture risk in men with osteoporosis. Research indicates that while ADT may initially decrease bone mineral density (BMD), some ADT regimens can stabilize or even increase BMD over time through indirect mechanisms, such as reducing bone turnover rates. Some Japanese studies have reported that ADT can lead to an initial decline in BMD. However, long-term outcomes are mixed, with certain regimens showing stabilization of BMD. The variability in BMD outcomes suggests that patient selection and specific ADT protocols are critical factors. The impact of ADT on quality of life in men with osteoporosis is complex. While ADT may contribute to the stabilization of bone health in some cases, it can also lead to adverse effects such as reduced libido, hot flashes, and fatigue, potentially diminishing overall quality of life [5,6].

Conclusion

The use of androgen deprivation therapy in Japanese males with osteoporosis represents a unique and complex treatment approach. While ADT offers potential benefits in stabilizing bone health, it is accompanied by significant challenges and adverse effects. Careful patient selection, comprehensive monitoring, and the integration of adjunctive therapies are critical to optimizing outcomes. Ongoing research and advancements in personalized medicine hold promise for improving the management of osteoporosis in men and addressing the complexities associated with ADT. As the field evolves, a nuanced and individualized approach will be essential to enhancing the quality of life and bone health in men with osteoporosis. Further research is needed to elucidate the mechanisms by which ADT influences bone remodeling in men with osteoporosis. Understanding these mechanisms can inform the development of targeted therapies that maximize bone health benefits while minimizing adverse effects. Long-term studies are essential to assess the sustained efficacy and safety of ADT in men with osteoporosis. Monitoring long-term fracture rates, cardiovascular outcomes, and quality of life will provide valuable insights into the overall impact of ADT in this population. Advancements in personalized medicine, including genetic and biomarker research, may enable more precise identification of patients who are likely to benefit from ADT. Personalized treatment strategies can optimize outcomes and minimize risks.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Poppe, K. and B. Velkeniers. "Thyroid and infertility." Verhandelingen-Koninklijke Academie voor Geneeskunde van Belgie 64 (2002): 389-99.

Google Scholar, Crossref, Indexed at

2. Ghassabian, Akhgar, Jacoba J. Bongers-Schokking, Jens Henrichs and Vincent WV Jaddoe, et al. "Maternal thyroid function during pregnancy and behavioral problems in the offspring: The generation R study." Pediatr Res 69 (2011): 454-459.

Google Scholar, Crossref, Indexed at

3. Krassas, Gerasimos, Spyridon N. Karras and Nikolaos Pontikides. "Thyroid diseases during pregnancy: A number of important issues." Hormones 14 (2015): 59-69.

Google Scholar, Crossref, Indexed at

4. Poppe, Kris, Daniel Glinoer, Herman Tournaye and Johan Schiettecatte, et al. "Thyroid function after assisted reproductive technology in women free of thyroid disease." Fertility and sterility 83 (2005): 1753-1757.

Google Scholar, Crossref, Indexed at

5. Gaberšček, Simona and Katja Zaletel. "Thyroid physiology and autoimmunity in pregnancy and after delivery." Expert Rev Clin Immunol 7 (2011): 697-707.

Google Scholar, Crossref, Indexed at

6. Foda, Abd AlRahman Mohammad, Mariya Syed Alam, Nadeem Ikram and Samia Rafi, et al. "Spinal vs. intracranial meningioma: Expression of E-cadherin and fascin with relation to clinicopathological features." Cancer Biomark 25 (2019): 333-339.

Google Scholar, Crossref, Indexed at